Pathology Oncology Research

, Volume 7, Issue 1, pp 39–41 | Cite as

HLA-DRB 1 alleles and the susceptibility of Iranian patients with breast cancer

  • A. Ghaderi
  • A. Talei
  • B. Gharesi-Fard
  • Sh. Farjadian
  • A. Amirzargar
  • M. Vasei


Breast cancer is considered a major malignancy among women worldwide. The contribution of genetic elements to the onset of familial breast cancer has already been established. The current study investigate the alfele frequency of HLA-DRB 1 in 36 primary operable female breast cancer patients from southern Iran by polymerase chain reaction using sequence specific primers (PCR-SSP). Results were compared with those of 36 female control subjects. Statistical analysis was performed and P values were determined for each character. Our results indicated that the frequency of HLA-DRB 1*12 allele is significantly higher in the patient group (p<0.03) compared to the control group. In addition, HLA-DRB1*11 appeared to be as the most frequent allele in the control group (29.2%) and had approximately the same distribution among the patient group (22.5%).


breast cancer HLA-DRB1 PCR-SSP 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.2
    Garfinkel I, Catherine C, Boring MPH, et al: An overview of breast cancer incidence and mortality. Cancer 74:222–227, 1994.PubMedCrossRefGoogle Scholar
  2. 2.2
    Szabo CI, King MC: Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60:1013–1020, 1997.PubMedGoogle Scholar
  3. 3.2
    Miki Y, Swense J, Shatuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility. Science 266:66–71, 1994.PubMedCrossRefGoogle Scholar
  4. 4.2
    Reiter DJ, Brocker EB, Ferrone S: Expression and susceptibility of modulation by interferones of HLA-class I and II antigens on melanoma cells. Immunohistochemical analysis and clinical relevance. J Immunogenetics 13:229–234, 1986.CrossRefGoogle Scholar
  5. 5.2
    Glew SS, Duggan-Keen M, Cabrera T, et al: HLA-class II antigen expression in human papilomavirus-associated cervical cancer. Cancer Res 52:4009–4016, 1992.PubMedGoogle Scholar
  6. 6.2
    Paterson AC, Sciot R, Kew MC, et al: HLA expression in human hepatocellular carcinoma. Br J Cancer 57:369–373, 1988.PubMedGoogle Scholar
  7. 7.2
    vanden Ingh HF, Ruiter DJ, Griffioen G, et al: HLA antigens in colorectal tumours-low expression of HLA class I antigens in mucinous colorectal carcinomas. Br J Cancer 55:125–130, 1987.PubMedGoogle Scholar
  8. 8.2
    Tokumoto H: Analysis of HLA-DRB1-related alleles in Japanese patients with lung cancer-relationship to genetic susceptibility and resistance to lung cancer. J Cancer Res Clin Oncol 124:511–516, 1988.CrossRefGoogle Scholar
  9. 9.2
    Graham DE: The isolation of high molecular weight DNA from whole organisms or large tissue masses. Anal Biochem 85:609–613, 1978.PubMedCrossRefGoogle Scholar
  10. 10.2
    Miller SA, Dykes DD, Polesky IF: A simple sahing out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 16:1215, 1988.CrossRefGoogle Scholar
  11. 11.2
    Olerup O, Zetterquist H: HLA-DR typing by PCR amplification with PCR-SSP in two hours. Tissue Antigens 39:225–235, 1992.PubMedCrossRefGoogle Scholar
  12. 12.2
    Casoli C, Zanelli P, Adorni A, et al: Serological and molecular study on the HLA phenotype of female breast cancer patients. Europ J Cancer 30A:1207–1208, 1994.CrossRefGoogle Scholar
  13. 13.2
    Pardon DM, Topalian SI: The role of CD4+ T cells responses in antitumor immunity. Curr Opin Immunol 10:588–589, 1998.CrossRefGoogle Scholar
  14. 14.2
    Armstrong ID, Elements VK, Ostrand-Rosenberg S: MHC class II-transfected tumor cells directly present antigen to tumor specific CD4+ T lymphocytes. J Immunol 160:660–666, 1998.Google Scholar
  15. 15.2
    Armstrong TD, Elements VK, Ostrand-Rosenberg S: ClassIItransformed tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigen in vivo. J Immunother 21:218–224, 1998.PubMedCrossRefGoogle Scholar
  16. 16.2
    Feinmesser M, Sulkes A, Morgenstern S, et al: HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities. J Clin Pathol 53:286–291, 2000.PubMedCrossRefGoogle Scholar
  17. 17.2
    Dadmarz R, Sgagias MK, Rosenberg SA, et al: CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol Immunother 40:1–9, 1995.PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2001

Authors and Affiliations

  • A. Ghaderi
    • 1
  • A. Talei
    • 2
  • B. Gharesi-Fard
    • 1
  • Sh. Farjadian
    • 1
  • A. Amirzargar
    • 1
  • M. Vasei
    • 3
  1. 1.Department of Immunology, Medical SchoolShiraz University of Medical SciencesShirazIran
  2. 2.Department of Surgery, Medical SchoolShiraz University of Medical SciencesShirazIran
  3. 3.Department of Pathology, Medical SchoolShiraz University of Medical SciencesShirazIran

Personalised recommendations